Skip to main content

Waters to Buy Back Stock

NEW YORK (GenomeWeb News) – Waters today said that its board of directors has authorized the firm to repurchase up to $500 million of its outstanding common stock over the next 24 months.

The firm's previous $500 million share repurchase program, which began in February 2007, had recently expired. Waters said that that repurchase program was "substantially completed."

It said that it would make purchases of its shares through open-market transactions.

Waters' shares were trading down 1 percent at $34.70 in early Monday trade on the New York Stock Exchange.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.